A rare endocrine condition called hypoparathyroidism frequently causes high calcium and phosphate levels, which in turn cause the parathyroid hormone (PTH) to be produced at low or abnormal levels. The market for treating hypoparathyroidism is predicted to reach US$ 717.7 million in 2021 and show a promising CAGR of around 8% through the end of the forecast period in 2031, according...
English 
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek